PPT-CROI 2015: HIV Prevention Updates

Ruanne V Barnabas MBChB Dphil Global Health and Medicine University of Washington a bevy of new studies quelled most remaining doubts about the realworld effectiveness of whats known as preexposure prophylaxis . Despite this signi64257cant progress the number of children becoming newly infected with HIV remains unacceptably high About 240 000 210 000280 000 children became infected with HIV in 2013 The risk of a mother living with HIV passing the virus to h Introduction. Access to HIV services as key component of HIV response among sex workers. Vital elements of HIV prevention and care continuum (HIV prevention, testing and treatment). Challenges to sex workers’ access to HIV related services in Europe. By Charles . Olusegun. DOHERTY. Background. The . Project was . premised on the fact that many . programmes. and activities on HIV and AIDS have never been taking into cognizance the inclusion of persons with Disabilities (PWD) in . Nina Kim, MD . Associate Professor of Medicine. Division of Allergy & Infectious Diseases. University of Washington. No financial conflicts of interest. ION-4. Ledipasvir-Sofosbuvir. for 12 weeks. Leveraging Programs, Policies and Partnerships. PRESENTORS. JACKSON. . STATE. . UNIVERSITY. Ollie Harper, R.N.C., WHCNP, MPPA . - Victoria Coleman, . HIV Coordinator. - France White, Therapist LNC . Division of HIV/AIDS Prevention. Centers for Disease Control and Prevention. Burden of HIV in the United States. . . 1.2 M . ~. 50K. 1.2 million people . living with HIV. Approximately . 50,000 new infections annually. T. oolbox?. Objectives for Module 1. Our . Mission(s) . Today:. Discuss the difference between HIV prevention for HIV-negative people, HIV prevention for people living with HIV, and HIV testing. Discuss . FOR THOSE AT RISK . Robinah. . Nakabugo. , ICW EA. The future with . PrEP. in combination HIV prevention . WHO . &. UNAIDS, Geneva, Switzerland. Wednesday 25. th. March 2015. Background to the presentation. Résumé scientifique des principales études cliniques présentées à la CROI 2019. CAHR is pleased to provide this scientific summary of the major clinical studies presented at the Conference on Retroviruses and Opportunistic Infections (CROI 2019). The synthesis aims to improve the cascade of care by increasing the skills and knowledge of Canadian health care professionals working in the realm of HIV. This presentation was made possible with the support of an educational grant from ViiV Healthcare.. AND OPPORTUNISTIC INFECTIONS. CROI 2023. 19-23 FEBRUARY 2023. Faculty. Pedro . Cahn. , Buenos-Aires, Argentina. Anton . Pozniak. , London, UK. François . Raffi. , Nantes, France. Long Acting Therapies. Brian R. Wood, MD. Assistant Professor of Medicine, University of Washington. Medical Director, NW AETC ECHO. March 5, 2015. ECHO CROI Reviews 2015. 3/5/15. 3/12/15. 3/19/15. Brian Wood: . Primary Care. Shireesha Dhanireddy. Robert Harrington. March 17, 2014. No financial conflicts of interest. Outline. Treatment Studies. Tenofovir. . alafenamide. (TAF) in a single-tablet regimen in initial HIV-1 infection . San . Francisco Department . of Public Health. Clinical Professor of Medicine and Epidemiology. University of California San Francisco. San Francisco, California. Maximizing the Benefits of . Pre-Exposure Prophylaxis (. Judith S. Currier, MD, MSc. Professor of Medicine. University of California Los Angeles. Financial Relationships With Ineligible Companies (Formerly Described as Commercial Interests by the ACCME) Within the Last 2 Years:.